Vaccines and Global Health: The Week in Review :: 22 Feb 2020

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: Vaccines and Global Health_The Week in Review_22 Feb 2020

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

EMERGENCIES

Emergencies

Editor’s Note:
While we have concentrated the most current key reports just below, COVID-19 announcements, analysis and commentary will be found throughout this issue, in all sections.
Beyond the considerable continuing coverage in the global general media:
Daily WHO situation reports here: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
WHO Coronavirus disease (COVID-2019) daily press briefings here: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/press-briefings

Coronavirus [COVID-19]
Public Health Emergency of International Concern (PHEIC)
Situation report – 33 [WHO]

Novel Coronavirus (COVID-19)
22 February 2020
[Excerpts]
SITUATION IN NUMBERS
Globally :: 77,794 laboratory-confirmed [599 new]
[Week ago: 49,053 laboratory-confirmed [2056 new]]
China :: 76,392 laboratory-confirmed [397 new]
:: 2,348 deaths [109 new]
Outside of China
:: 1,402 laboratory-confirmed [58 new]
:: 28 countries
:: 11 deaths [1 new]

WHO RISK ASSESSMENT
China – Very High
Regional Level – High
Global Level – High

HIGHLIGHTS
:: Two new countries (Lebanon and Israel) reported cases of COVID-19 in the past 24 hours.
:: The role of environmental contamination in the transmission of COVID-19 is not yet clear. On 18 February, a new protocol entitled “Surface sampling of coronavirus disease (COVID-19): A practical “how to” protocol for health care and public health professionals” was published. This protocol was designed to determine viable virus presence and persistence on fomites in various locations where a COVID-19 patient is receiving care or isolated, and to understand how fomites may play a role in the transmission of the virus.
:: The WHO Director-General briefed the emergency ministerial meeting on COVID-19 organized by the African Union and the Africa Centres for Disease Control and Prevention. Details can be found here.

::::::

National Health Commission of the People’s Republic of China
http://en.nhc.gov.cn/
Selected News & Announcements
Feb 22: Daily briefing on novel coronavirus cases in China
On Feb 21, 31 provincial-level regions on the Chinese mainland as well as the Xinjiang Production and Construction Corps reported 397 new cases of confirmed infections, 1,361 new cases of suspected infections, and 109 deaths.
[See Emergencies above for detail]

China races to develop vaccines against coronavirus
2020-02-21
BEIJING — Chinese scientists are racing to develop vaccines against the novel coronavirus by adopting five technological approaches, a senior National Health Commission official said on Feb 21.
“Some projects have entered the stage of animal testing,” Zeng Yixin, deputy director of the commission, told a news conference on China’s fight against the novel coronavirus outbreak.
“Under the premise of ensuring safety, effectiveness and accessibility (of vaccines), (we) foresee that as soon as from April to May this year some vaccines could enter clinical trials, or under specific conditions, could be applied for emergency use,” he said.
“Our goal is that if required by the outbreak situation, the emergency use of vaccines, as well as the emergency review and approval process, can be activated in accordance with laws,” the official said.

 

::::::

Johnson & Johnson to Expand Partnership with U.S. Department of Health & Human Services to Accelerate the Discovery of Potential COVID-19 Treatments
NEW BRUNSWICK, N.J., Feb. 18, 2020 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced that its Janssen Pharmaceutical Companies will expand its existing partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services, to seek treatment solutions for COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2 (also known as 2019-nCoV). This latest collaboration will enhance Janssen’s ongoing work with global partners to screen a library of existing antiviral molecules, with the aim of identifying compounds with promising antiviral activity against SARS-CoV-2.
The expanded partnership with BARDA builds on Johnson & Johnson’s multipronged response to the COVID-19 outbreak. These efforts, in addition to the ongoing development of a potential vaccine candidate, bring hope of finding a solution against COVID-19 for communities in greatest need in China and around the world…

 

::::::
::::::

WHO Director General – Speeches Emergency Ministerial meeting on COVID-19 organized by the African Union and the Africa Centres for Disease Control and Prevention

Milestones :: Perspectives :: Research

 

WHO Director General – Speeches

Emergency Ministerial meeting on COVID-19 organized by the African Union and the Africa Centres for Disease Control and Prevention
22 February 2020
Your Excellency Mr Moussa Faki Mahamat, Chairperson of the African Union Commission, Commissioner Amira El Fadil, WHO Regional Director Dr Matshidiso Moeti and Director John Nkengasong,
[Excerpts]
Excellencies, dear colleagues and friends,
…It’s hard to believe that only 52 days ago, WHO’s country office in China was notified of a cluster of cases of pneumonia of unknown cause in Wuhan city.

 

In just seven weeks, this outbreak has captured the world’s attention, and rightly so, because it has the potential to cause severe political, social and economic upheaval.  

…The data from China continue to show a decline in new cases. This is welcome news, but it must be interpreted very cautiously. It’s far too early to make predictions about this outbreak.
Outside China, there are now 1200 cases in 26 countries, with 8 deaths. As you know, there is one confirmed case on the African continent, in Egypt.

Several African countries have tested suspected cases of COVID-19, but fortunately they have been found negative.

Although the total number of cases outside China remains relatively small, we are concerned about the number of cases with no clear epidemiological link, such as travel history to China or contact with a confirmed case.

We are especially concerned about the increase in cases in the Islamic Republic of Iran, where there are now 18 cases and four deaths in just the past two days. WHO has supplied testing kits to Iran, and we will continue to provide further support in the coming days and weeks. What has been reported from South Korea and Italy yesterday is also a matter of concern and how the virus is now spreading to other parts of the world. But in addition to that, as I said earlier in my press conference, the window of opportunity is narrowing. This meeting, I hope, will help us come together as a continent in attacking this virus.

 

As you know, a WHO-led international team of experts – including a representative from the Nigerian CDC, our colleague Chikwe Ihekweazu, has been on the ground in China for the past week, visiting three provinces, and is today traveling to the epicenter in Wuhan.

With every day that passes, we know a little bit more about this virus, and the disease it causes.

We know that more than 80% of patients have mild disease and will recover. But the other 20% of patients have severe or critical disease, ranging from shortness of breath to septic shock and multi-organ failure. These patients require intensive care, using equipment such as respiratory support machines that are, as you know, in short supply in many African countries. And that’s a cause for concern.

In 2% of reported cases, the virus is fatal, and the risk of death increases the older a patient is, and with underlying health conditions. We see relatively few cases among children. More research, of course, is needed to understand why.

Our biggest concern continues to be the potential for COVID-19 to spread in countries with weaker health systems. And I said earlier, our Africa regional office in partnership with the Africa CDC — we’re working hard to prepare countries in Africa for the potential arrival of the virus.

WHO has identified 13 priority countries in Africa because of their direct links to China or their high volume of travel with China. As my sister Tshidi said, an increasing number of African countries are now able to test for COVID-19 with laboratory test kits supplied by WHO, compared with only one just a couple of weeks ago.

Some countries in Africa, including DRC, are also leveraging the capacity they have built up to test for Ebola, to test for COVID-19. This is a great example of how investing in health systems can pay dividends for health security.

 

We have also shipped more than 30,000 sets of personal protective equipment to several countries in Africa, and we’re ready to ship almost 60,000 more sets to 19 countries in the coming weeks.

We’re working with manufacturers of personal protective equipment to address the severe disruption in the market for masks, gloves, gowns and other PPE, to ensure we can protect health workers.

 

During the past month about 11,000 African health workers have been trained using WHO’s online courses on COVID-19, which are available free of charge in English, French and other languages at OpenWHO.org.

We’re also providing advice to countries on how to do screening, testing, contact tracing and treatment.

Last week we brought the international research community together to identify research priorities, especially in the areas of diagnostics, therapeutics and vaccines.

 

Two weeks ago, I briefed the UN Secretary-General Antonio Guterres, and we agreed to activate the United Nations Crisis Management Team, led by Dr Mike Ryan, to enable WHO to focus on the health response while other agencies bring their expertise to bear on the social, economic and developmental implications of the outbreak.

We have also held two calls with UN resident coordinators all over the world, to brief them on the actions they can take to prepare their countries and ensure the United Nations system is working as one. And I hope, your excellencies, ministers, that you will work with our resident coordinators and WHO representatives to respond in a very coordinated fashion at country level.

 

The increasing signs of transmission outside China show that the window of opportunity we have for containing this virus is narrowing.

We are calling on all countries to invest urgently in preparedness. We have to take advantage of the window of opportunity we have, to attack  the virus outbreak with a sense of urgency.

Thank you all for your attention to this issue. I assure you that WHO is committed to working with all African countries to do everything we can to prevent transmission and detect and treat cases as early as possible.

Emergencies – Ebola

Emergencies

Ebola – DRC+
Public Health Emergency of International Concern (PHEIC)

Ebola Outbreak in DRC 80: 16 February 2020
[Excerpts]
Situation Update
This week, the incidence of Ebola virus disease (EVD) cases continued to be low (Figure 1). From 10 to 16 February 2020, one new confirmed case was reported in Beni Health Zone, North Kivu Province in Democratic Republic of the Congo. The case was reported on 11 February 2020, and was listed and followed as a contact at the time of detection, with known epidemiological links. Early detection of cases reduces the probability of transmission of EVD in the community and significantly improves the clinical outcome for the patients…

While we are cautiously optimistic about the overall trend and reduced geographic spread of the outbreak, the security situation in several EVD-affected health areas remain volatile, and the risk of spread within Democratic Republic of the Congo and neighbouring countries remains high. Given delays in isolation of some cases in recent weeks and continued reports of nosocomial transmission, we expect to see additional cases in the coming weeks. It is critical that response teams rapidly detect, investigate and follow-up all cases and their contracts…

…Conclusion
While there is room for cautious optimism around the low number of new confirmed cases reported in recent weeks, the situation remains fragile and further cases should be expected. It is important to ensure continued access and heightened vigilance for response activities, including early case identification, contact tracing, and improving infection prevention and control measures in healthcare facilities.

 

::::::
::::::

WHO & Regional Offices [to 22 Feb 2020]

WHO & Regional Offices [to 22 Feb 2020]
19 February 2020 News release
World failing to provide children with a healthy life and a climate fit for their future: WHO-UNICEF-Lancet

 

::::::

Weekly Epidemiological Record, 21 February 2020, vol. 95, 08 (pp. 69–76)
:: Progress towards measles elimination – China, January 2013–June 2019
:: COVID-19 update

 

::::::

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: WHO pledges to support African countries on joint coronavirus disease preparedness a…
22 February 2020
:: Polio-Nigeria leaves no stone unturned, targets over 55 million children in house-to…
20 February 2020

WHO Region of the Americas PAHO
:: Update on COVID-19 in the Region of the Americas
Washington, DC, February 20, 2020 (PAHO) – The Pan American Health Organization (PAHO) has announced a total of 23 confirmed cases of coronavirus 2019 (COVID-19) in the Region of the Americas. As of 18 February, all cases were reported in the United States (15) and Canada (8)…

WHO South-East Asia Region SEARO
No new digest content identified.

WHO European Region EURO
:: Towards an agreement for improving access to high-cost medicines 21-02-2020

WHO Eastern Mediterranean Region EMRO
:: Polio eradication on United Nations Secretary General’s agenda during Pakistan visit
18 February 2020

WHO Western Pacific Region
No new digest content identified.

CDC/ACIP [to 22 Feb 2020]

CDC/ACIP [to 22 Feb 2020]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
ACIP Meetings
Next ACIP Meeting: February 26-27, 2020
Agenda (Draft) pdf icon[2 pages]

Latest News Releases
:: Transcript for CDC Telebriefing: Update on COVID-19 Friday, February 21, 2020

MMWR News Synopsis Friday, February 21, 2020
Interim Estimates of 2019–20 Seasonal Influenza Vaccine Effectiveness — United States, February 2020
CDC preliminary vaccine effectiveness estimates indicate that the 2019-20 flu vaccine is providing substantial protective benefit, particularly among children, who were hard hit by flu this season. Flu vaccines are reducing doctor visits associated with flu illness by 45% overall and 55% in children. CDC’s interim flu vaccine effectiveness (VE) estimates show that the flu vaccine has reduced doctor visits associated with flu illness by almost half (VE = 45%) so far this season. This is consistent with estimates of flu vaccine effectiveness from previous seasons that ranged from 40%-60% when flu vaccine viruses were similar to circulating flu viruses. Vaccination is providing substantial protection (VE = 55%) for children, who have been particularly hard hit by flu this season.

Africa CDC [to 22 Feb 2020]

Africa CDC [to 22 Feb 2020]
http://www.africacdc.org/
News
Eighty experts participate in training on enhanced surveillance at points of entry
ADDIS ABABA, ETHIOPIA, 17 FEBRUARY 2020. Eighty participants from 18 African countries are participating in a training on enhanced surveillance at points of entry currently holding in Narobi, Kenya, for points of entry surveillance officers, national surveillance officers, airport authority officers, and representatives of airlines.   The training is organized by the Africa Centres for Disease Control and Prevention in…
Actions taken include training representatives of Member States in laboratory testing of coronavirus, infection prevention and control, risk communication, and surveillance. Africa CDC is also supporting countries to source for and obtain reagents needed to rapidly test for the virus.
This training is to strengthen capacity in the continent and ensure standardization of points of entry surveillance by the different countries so they can quickly detect and contain the outbreak while at its lowest magnitude in the continent…

 

China CDC

China CDC
http://www.chinacdc.cn/en/
No new digest content identified.

 

National Health Commission of the People’s Republic of China
http://en.nhc.gov.cn/
News
Feb 22: Daily briefing on novel coronavirus cases in China
On Feb 21, 31 provincial-level regions on the Chinese mainland as well as the Xinjiang Production and Construction Corps reported 397 new cases of confirmed infections, 1,361 new cases of suspected infections, and 109 deaths.
[See Emergencies above for detail]

China races to develop vaccines against coronavirus
2020-02-21
BEIJING — Chinese scientists are racing to develop vaccines against the novel coronavirus by adopting five technological approaches, a senior National Health Commission official said on Feb 21.
“Some projects have entered the stage of animal testing,” Zeng Yixin, deputy director of the commission, told a news conference on China’s fight against the novel coronavirus outbreak.
“Under the premise of ensuring safety, effectiveness and accessibility (of vaccines), (we) foresee that as soon as from April to May this year some vaccines could enter clinical trials, or under specific conditions, could be applied for emergency use,” he said.
“Our goal is that if required by the outbreak situation, the emergency use of vaccines, as well as the emergency review and approval process, can be activated in accordance with laws,” the official said.

Announcements

Announcements

Sabin Vaccine Institute Launches Vaccine Acceptance and Demand Program — Now recruiting for a number of positions
Senior Manager, Vaccine Acceptance
Reports to: Vice President, Vaccine Acceptance and Demand Location: Washington, DC
Vice President, Vaccine Acceptance and Demand
Reports to: President, Global Immunization Location: Washington, DC
Senior Manager, Social Media Research
Reports to: Vice President, Vaccine Acceptance and Demand Location: Washington, DC
Senior Manager, Immunization Advocates
Reports to: Vice President, Vaccine Acceptance and Demand Location: Washington, DC

 

Vaccine Confidence Project [to 22 Feb 2020]
http://www.vaccineconfidence.org/
Latest News & Archive
World must fight anti-vaccine drive, says Women in Science winner from Bangladesh
18 February 2020

 

Vaccine Education Center – Children’s Hospital of Philadelphia [to 22 Feb 2020]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.

 

Wellcome Trust [to 22 Feb 2020]
https://wellcome.ac.uk/news
Opinion | 20 February 2020
Ideas to reimagine research culture: what we’ve heard at our university town halls
by Ben Bleasdale

Opinion | 19 February 2020
COVID-19: how researchers around the world are racing to understand the virus and prevent future outbreaks
by Josie Golding
As the outbreak of COVID-19 continues to spread in China and countries around the world, a global community of researchers are working to find out more about the virus and assess what research needs to be done to stop it.

 

The Wistar Institute [to 22 Feb 2020]
https://www.wistar.org/news/press-releases
Press Releases
Feb. 19, 2020
New Molecular Mechanism Involved in Cellular Senescence That Modulates Inflammation and Response to Cancer Immunotherapy
The newly identified pathway may be modulated during chemotherapy to enable response to immune checkpoint blockade.

 

World Organisation for Animal Health (OIE) [to 22 Feb 2020]
https://www.oie.int/en/for-the-media/press-releases/2020/
Press Releases
2nd OIE Rinderpest Challenge: the winners
Today, the World Organisation for Animal Health (OIE) announces the winners of the 2nd OIE Rinderpest Challenge. For four weeks, players across the globe competitively diagnosed livestock and helped laboratories manage at-risk materials in order to find the virtual outbreak of Rinderpest. The challenge is now closed, yet players can continue to train!
Paris, 12 February 2020 – Over 12,300 participants from 121 countries participated in the 2nd OIE Rinderpest Challenge between 15 January and 12 February 2020. An exciting opportunity which gathered ten times more participants than the first edition held in 2019. For the past four weeks, participants have been playing the serious game to collect points for their countries. Meanwhile, they learned how to diagnose Rinderpest among several other diseases with similar clinical signs, as well as how to cautiously handle materials that potentially contain the rinderpest virus in laboratories.
According to the points displayed on the leaderboard at the close of the challenge, Uzbekistan is the winning country. With a total of 4,129,060 points, a new record has been set…

::::::

ARM [Alliance for Regenerative Medicine] [to 22 Feb 2020]
https://alliancerm.org/press-releases/
Press Releases
No new digest content identified.

 

BIO [to 22 Feb 2020]
https://www.bio.org/press-releases
Press Releases
BIO Asia Conference in Tokyo Cancelled Amid
COVID-19 Outbreak

Washington, DC – February 21, 2020 – The Biotechnology Innovation Organization (BIO) announced today, it is canceling the annual BIO Asia conference in Tokyo scheduled for March 10-11. The decision was based on the global impact of COVID-19 and Japanese government recommendations.
“Our attendees’ health and safety are our utmost priority,” said Jim Greenwood, BIO President & CEO. “We offer our support and sympathy to all of those who’ve been impacted by the virus around the world.”…

 

DCVMN – Developing Country Vaccine Manufacturers Network [to 22 Feb 2020]
http://www.dcvmn.org/
News
Advanced Pharmacovigilance workshop and WG meeting
16 March 2020 to 19 March 2020, Shanghai / China

 

IFPMA [to 22 Feb 2020]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.
PhRMA [to 22 Feb 2020]
http://www.phrma.org/
Selected Press Releases, Statements
Helping those affected by the coronavirus
Stephen J. Ubl   |     February 20, 2020
America’s biopharmaceutical companies are committed to developing solutions to help diagnose and treat those with COVID-19, a novel strain of coronavirus that originated in Wuhan, China. In addition to applying their scientific expertise to find ways to diagnose, treat and prevent infections from the virus, the biopharmaceutical industry is providing financial support and in-kind donations to organizations and collaborating with U.S., Chinese and global health authorities to combat this global public health emergency.
More than half of PhRMA members have R&D efforts under way or are providing donations of medicines and critical medical supplies as well as providing financial donations to support patients and first responders in addressing this evolving crisis…

Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Maximizing the impact of, and sustaining standing orders protocols for adult immunization in outpatient clinics

American Journal of Infection Control
March 2020 Volume 48, Issue 3, p239-354
http://www.ajicjournal.org/current

 

Major Articles
Maximizing the impact of, and sustaining standing orders protocols for adult immunization in outpatient clinics
L.J. Tan, Robin VanOss, Cori L. Ofstead, Harry P. Wetzler
p290–296
Published online: October 18, 2019
Open Access

The Potential Economic Value of a Zika Vaccine for a Woman of Childbearing Age

American Journal of Preventive Medicine
March 2020 Volume 58, Issue 3, p313-472
http://www.ajpmonline.org/current

 

Research Articles
The Potential Economic Value of a Zika Vaccine for a Woman of Childbearing Age
Sarah M. Bartsch, Lindsey Asti, Owen J. Stokes-Cawley, So Yoon Sim, Maria Elena Bottazzi, Peter J. Hotez, Bruce Y. Lee
p370–377
Published online: January 20, 2020

Human Papillomavirus Vaccination Schedule: Adherence Among Commercially Insured Adolescents and Young Adults in the United States, 2011–2017

American Journal of Public Health
March 2020 110(33)
http://ajph.aphapublications.org/toc/ajph/current

 

HUMAN PAPILLOMAVIRUS VACCINE
Human Papillomavirus Vaccination Schedule: Adherence Among Commercially Insured Adolescents and Young Adults in the United States, 2011–2017
Demetria Hubbard, Sadeep Shrestha, Emily B. Levitan and Huifeng Yun
110(3), pp. 385–390

Legal Uncertainty—The Gray Area around Substandard Medicines: Where Public Health Meets Law

American Journal of Tropical Medicine and Hygiene
Volume 102, Issue 2, February 2020
http://www.ajtmh.org/content/journals/14761645/102/2

 

Perspective Pieces
Legal Uncertainty—The Gray Area around Substandard Medicines: Where Public Health Meets Law
Eugenia Olliaro, Piero Olliaro, Calvin W. L. Ho and Raffaella Ravinetto
Pages: 262–267
https://doi.org/10.4269/ajtmh.19-0645

Impact of mother’s education on full immunization of children aged 12–23 months in Eritrea: population and health survey 2010 data analysis

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 22 Feb 2020)

 

Impact of mother’s education on full immunization of children aged 12–23 months in Eritrea: population and health survey 2010 data analysis
Although vaccination coverage in Eritrea has improved in recent years, some children are still missing out, and it’s important to identify risk factors for lower coverage in order to target campaigns and inter…
Authors: Fitsum Kibreab, Sonia Lewycka and Andebrhan Tewelde
Citation: BMC Public Health 2020 20:267
Content type: Research article
Published on: 22 February 2020

Health workers’ perceptions and challenges in implementing meningococcal serogroup a conjugate vaccine in the routine childhood immunization schedule in Burkina Faso

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 22 Feb 2020)

 

Health workers’ perceptions and challenges in implementing meningococcal serogroup a conjugate vaccine in the routine childhood immunization schedule in Burkina Faso
Meningococcal serogroup A conjugate vaccine (MACV) was introduced in 2017 into the routine childhood immunization schedule (at 15–18 months of age) in Burkina Faso to help reduce meningococcal meningitis burde…
Authors: Sylvain F. Nkwenkeu, Mohamed F. Jalloh, Jenny A. Walldorf, Robert L. Zoma, Felix Tarbangdo, Soukeynatou Fall, Sansan Hien, Roland Combassere, Cesaire Ky, Ludovic Kambou, Alpha Oumar Diallo, Akshaya Krishnaswamy, Flavien H. Aké, Cynthia Hatcher, Jaymin C. Patel, Isaïe Medah…
Citation: BMC Public Health 2020 20:254
Content type: Research article
Published on: 19 February 2020

Conjectures, refutations and the search for truths : Science, symbolic truths and the devil

EMBO Reports
Volume 21 Issue 2 5 February 2020
https://www.embopress.org/toc/14693178/current

 

Science & Society 13 January 2020 Open Access
Conjectures, refutations and the search for truths : Science, symbolic truths and the devil
G Paolo Dotto
In times of fake news, post‐truths and post‐science, the principles of science can inform all kinds of inquiries into the true nature of reality.
Science & Society15 January 2020 Open Access

Real‐time ethics engagement in biomedical research : Ethics from bench to bedside

EMBO Reports
Volume 21 Issue 2 5 February 2020
https://www.embopress.org/toc/14693178/current

Real‐time ethics engagement in biomedical research : Ethics from bench to bedside
Jeremy Sugarman, Annelien L Bredenoord

Biomedical research inevitably involves ethical issues. Some raise broad public concerns, particularly when researchers obviously violate established ethical norms. For example, He Jiankui’s work using CRISPR/Cas9 to genetically modify human embryos to prevent HIV transmission, which resulted in the birth of the world’s first two gene‐edited babies, generated widespread condemnation of this use of human germline modifications. Ethical issues also arise in the earlier phases of basic research, such as the public release of the HeLa cell genome by the European Molecular Biological Laboratory that created controversy over privacy concerns. At other times, ethical issues are more subtle and may not be recognized as such or raise public concern. For instance, there are important ethical considerations related to using banked biospecimens in translational research. Similarly, creating neurological chimeric mouse models involves moral considerations related to the potential humanization of these models 1, and embryo models from human stem cells are entangled in debates about the moral status of the embryo 2.
Nonetheless, efforts should be taken to identify and manage ethical issues as early as possible in order to provide ethical guidance throughout the entire research process, and mitigate negative effects, harms and wrongs (K.R. Jongsma & A.L. Bredenoord, under review). In this paper, we describe how ethics expertise can contribute to biomedical research through real‐time engagement and some of the challenges associated with such efforts. To do so, we offer our experiences with two particular examples: organoid technology and umbilical cord blood (UCB) banking and transplantation…

Towards a European health research and innovation cloud (HRIC)

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 22 Feb 2020]

 

Towards a European health research and innovation cloud (HRIC)
The European Union (EU) initiative on the Digital Transformation of Health and Care (Digicare) aims to provide the conditions necessary for building a secure, flexible, and decentralized digital health infrastructure. Creating a European Health Research and Innovation Cloud (HRIC) within this environment should enable data sharing and analysis for health research across the EU, in compliance with data protection legislation while preserving the full trust of the participants.
Authors: F. M. Aarestrup, A. Albeyatti, W. J. Armitage, C. Auffray, L. Augello, R. Balling, N. Benhabiles, G. Bertolini, J. G. Bjaalie, M. Black, N. Blomberg, P. Bogaert, M. Bubak, B. Claerhout, L. Clarke, B. De Meulder…
Citation: Genome Medicine 2020 12:18
Content type: Opinion
Published on: 19 February 2020

Knowing antimicrobial resistance in practice: a multi-country qualitative study with human and animal healthcare professionals

Global Health Action
Volume 12, 2019 Issue 1
https://www.tandfonline.com/toc/zgha20/12/sup1?nav=tocList

 

Article
Knowing antimicrobial resistance in practice: a multi-country qualitative study with human and animal healthcare professionals
Maddy Pearson & Clare Chandler
Article: 1599560
Published online: 11 Jul 2019

Supporting the use of research evidence in decision-making in crisis zones in low- and middle-income countries: a critical interpretive synthesis

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 22 Feb 2020]

 

Supporting the use of research evidence in decision-making in crisis zones in low- and middle-income countries: a critical interpretive synthesis
Decision-makers in crisis zones are faced with the challenge of having to make health-related decisions under limited time and resource constraints and in light of the many factors that can influence their decisions, of which research evidence is just one. To address a key gap in the research literature about how best to support the use of research evidence in such situations, we conducted a critical interpretive synthesis approach to develop a conceptual framework that outlines the strategies that leverage the facilitators and address the barriers to evidence use in crisis zones.
Authors: Ahmad Firas Khalid, John N. Lavis, Fadi El-Jardali and Meredith Vanstone
Citation: Health Research Policy and Systems 2020 18:21
Content type: Research
Published on: 18 February 2020

Resource allocation for biomedical research: analysis of investments by major funders

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 22 Feb 2020]

 

Resource allocation for biomedical research: analysis of investments by major funders
Data on grants for biomedical research by 10 major funders of health research were collected from the World RePORT platform to explore what is being funded, by whom and where. This analysis is part of the Worl…
Authors: Ambinintsoa H. Ralaidovy, Taghreed Adam and Philippe Boucher
Citation: Health Research Policy and Systems 2020 18:20
Content type: Research
Published on: 17 February 2020

The National Gene Vector Biorepository: Eleven Years of Providing Resources to the Gene Therapy Community

Human Gene Therapy
Volume 31, Issue 3-4 / February 2020
https://www.liebertpub.com/toc/hum/31/3-4

 

Review
The National Gene Vector Biorepository: Eleven Years of Providing Resources to the Gene Therapy Community
Kenneth Cornetta, Lorraine Matheson, Ryan Long, and Lisa Duffy
Pages:145–150
Published Online:30 January 2020
Abstract
The National Gene Vector Biorepository (NGVB) program has been highly accessed by gene therapy investigators. The reagent repository has distributed over 1,000 reagents to 397 investigators. The Pharmacology/Toxicology Archive contains over 36,000 specimens from a variety of adeno-associated virus (AAV), adenoviral, and other pharmacology/toxicology studies. NGVB also maintains a searchable database of gene therapy pharmacology/toxicology studies to promote data sharing. NGVB has provided Food and Drug Administration (FDA)-mandated replication-competent virus testing for over 70 clinical trials. From 2008 to 2018, there have been 114 publications acknowledging the NGVB. It is unlikely that any other National Institutes of Health (NIH)-funded program has served as many gene therapy investigators as the NGVB.

The Crisis in Yemen

Humanitarian Exchange Magazine
Number 76, January 2020
https://odihpn.org/magazine/the-crisis-in-yemen/

 

The Crisis in Yemen
by HPN
This edition of Humanitarian Exchange focuses on the crisis in Yemen. Since the war there began in 2014, thousands of civilians have been killed or injured and air strikes and ground operations have destroyed hospitals, schools and critical infrastructure. An estimated 80% of Yemenis need humanitarian assistance.

In the lead article, Laurie Lee highlights the critical role Yemenis and Yemeni organisations are playing in addressing the humanitarian challenges in the country, and how NGOs can better support them. Genevieve Gauthier and Marcus Skinner reinforce this point with reference to two local organisations, the Yemen Women’s Union and Al Hikma. Warda Saleh, the founder of another Yemeni grassroots organisation, discusses the increased risk of gender-based violence facing women and girls, while Ibrahim Jalal and Sherine El Taraboulsi-McCarthy focus on internal displacement and the opportunities for a more effective humanitarian response. Reflecting on child protection programming in Yemen, Mohammed Alshamaa  and Amanda Brydon conclude that multisectoral approaches with local authorities result in better and more sustainable outcomes. Padraic McCluskey and Jana Brandt consider the ethical dilemmas Médecins Sans Frontières (MSF) faced in trying to balance quality and coverage in a mother and child hospital in Taiz. Lindsay Spainhour Baker and colleagues reflect on the challenges involved in gathering and analysing information on the humanitarian situation while Lamis Al-Iryani, Sikandra Kurdi and Sarah Palmer-Felgate discuss the findings from an evaluation of the Yemen Social Fund for Development (SFD) Cash for Nutrition programme. An article by Kristine Beckerle and Osamah Al-Fakih details Yemeni and international organisations’ efforts to document and mitigate harm to civilians caught up in the conflict. The edition ends with a piece by Fanny Pettibon, Anica Heinlein and Dhabie Brown outlining CARE’s advocacy on the arms trade.

Finally, readers will note that this edition is shorter than usual, largely because it was very difficult to persuade potential authors to write on the Yemen crisis. Many of the individuals and organisations we contacted were either too busy responding or were concerned that writing frankly about their work could negatively affect their operations. HPN has covered many similarly sensitive contexts in Humanitarian Exchange over the last 26 years, but this is the first time we have experienced such reluctance to engage. A worrying sign.

Ethical and Legal Aspects of Ambient Intelligence in Hospitals

JAMA
February 11, 2020, Vol 323, No. 6, Pages 491-580
http://jama.jamanetwork.com/issue.aspx

 

Viewpoint
Ethical and Legal Aspects of Ambient Intelligence in Hospitals
Sara Gerke, Dipl-Jur Univ, MA; Serena Yeung, PhD; I. Glenn Cohen, JD
free access has audio
JAMA. 2020;323(7):601-602. doi:10.1001/jama.2019.21699
This Viewpoint reviews the ethical and legal implications of using ambient intelligence, the use of artificial intelligence–based technologies to monitor health care and quality measures like handwashing and patient falls in health care setting.

Intergenerational monitoring in clinical trials of germline gene editing

Journal of Medical Ethics
March 2020 – Volume 46 – 3
http://jme.bmj.com/content/current

 

Original research
Intergenerational monitoring in clinical trials of germline gene editing (31 August, 2019)
Bryan Cwik
Abstract
Design of clinical trials for germline gene editing stretches current accepted standards for human subjects research. Among the challenges involved is a set of issues concerning intergenerational monitoring—long-term follow-up study of subjects and their descendants. Because changes made at the germline would be heritable, germline gene editing could have adverse effects on individuals’ health that can be passed on to future generations. Determining whether germline gene editing is safe and effective for clinical use thus may require intergenerational monitoring. The aim of this paper is to identify and argue for the significance of a set of ethical issues raised by intergenerational monitoring in future clinical trials of germline gene editing. Though long-term, multigenerational follow-up study of this kind is not without precedent, intergenerational monitoring in this context raises unique ethical challenges, challenges that go beyond existing protocols and standards for human subjects research. These challenges will need to be addressed if clinical trials of germline gene editing are ever pursued.

COVID-19: fighting panic with information :: COVID-19: what is next for public health?

The Lancet
Feb 22, 2020 Volume 395 Number 10224 p537-658, e33-e40
https://www.thelancet.com/journals/lancet/issue/current

 

Editorial
COVID-19: fighting panic with information
The Lancet
… It is the rapid dissemination of trustworthy information—transparent identification of cases, data sharing, unhampered communication, and peer-reviewed research—which is needed most during this period of uncertainty. There may be no way to prevent a COVID-19 pandemic in this globalised time, but verified information is the most effective prevention against the disease of panic.

Comment
COVID-19: what is next for public health?
David L Heymann, Nahoko Shindo
on behalf of the WHO Scientific and Technical Advisory Group for Infectious Hazards
The WHO Scientific and Technical Advisory Group for Infectious Hazards (STAG-IH), working with the WHO secretariat, reviewed available information about the outbreaks of 2019 novel coronavirus disease (COVID-19) on Feb 7, 2020, in Geneva, Switzerland, and concluded that the continuing strategy of containment for elimination should continue, and that the coming 2–3 weeks through to the end of February, 2020, will be crucial to monitor the situation of community transmission to update WHO public health recommendations if required…

Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries

The Lancet
Feb 22, 2020 Volume 395 Number 10224 p537-658, e33-e40
https://www.thelancet.com/journals/lancet/issue/current

 

Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries
Marc Brisson, et al

Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries

The Lancet
Feb 22, 2020 Volume 395 Number 10224 p537-658, e33-e40
https://www.thelancet.com/journals/lancet/issue/current

 

Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries
Karen Canfell, et al

Necessary voices

Nature Genetics
Volume 52 Issue 2, February 2020
https://www.nature.com/ng/volumes/52/issues/2

 

Editorial | 05 February 2020
Necessary voices
Given that it is based on heredity and has the ability to trace connections, genetics as a scientific discipline should be among those most attuned to diversity and global perspectives. Indigenous communities and scientists have much to contribute to genetics research, and they are making their voices heard. We celebrate these essential members of our larger genetics community, and we look forward to working together to learn from past examples, meet present challenges and support future opportunities.

A Novel Coronavirus Emerging in China — Key Questions for Impact Assessment

New England Journal of Medicine
February 20, 2020 Vol. 382 No. 8
http://www.nejm.org/toc/nejm/medical-journal

 

Perspective
A Novel Coronavirus Emerging in China — Key Questions for Impact Assessment
Vincent J. Munster, Ph.D., Marion Koopmans, D.V.M., Neeltje van Doremalen, Ph.D., Debby van Riel, Ph.D., and Emmie de Wit, Ph.D.
[Excerpt]
… We currently do not know where 2019-nCoV falls on the scale of human-to-human transmissibility. But it is safe to assume that if this virus transmits efficiently, its seemingly lower pathogenicity as compared with SARS, possibly combined with super-spreader events in specific cases, could allow large-scale spread. In this manner, a virus that poses a low health threat on the individual level can pose a high risk on the population level, with the potential to cause disruptions of global public health systems and economic losses. This possibility warrants the current aggressive response aimed at tracing and diagnosing every infected patient and thereby breaking the transmission chain of 2019-nCoV.
Epidemiologic information on the pathogenicity and transmissibility of this virus obtained by means of molecular detection and serosurveillance is needed to fill in the details in the surveillance pyramid and guide the response to this outbreak. Moreover, the propensity of novel coronaviruses to spread in health care centers indicates a need for peripheral health care facilities to be on standby to identify potential cases as well. In addition, increased preparedness is needed at animal markets and other animal facilities, while the possible source of this emerging virus is being investigated. If we are proactive in these ways, perhaps we will never have to discover the true epidemic or pandemic potential of 2019-nCoV.

High risk for human exposure to Rift Valley fever virus in communities living along livestock movement routes: A cross-sectional survey in Kenya

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 22 Feb 2020)

 

High risk for human exposure to Rift Valley fever virus in communities living along livestock movement routes: A cross-sectional survey in Kenya
Caroline Tigoi, Rosemary Sang, Edith Chepkorir, Benedict Orindi, Samuel Okello Arum, Francis Mulwa, Gladys Mosomtai, Samson Limbaso, Osama A. Hassan, Zephania Irura, Clas Ahlm, Magnus Evander
Research Article | published 21 Feb 2020 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0007979

2020 National Vaccine Plan Development: Recommendations From the National Vaccine Advisory Committee

Public Health Reports
Volume 135 Issue 2, March/April 2020
https://journals.sagepub.com/toc/phrg/135/2

 

Reports and Recommendations
2020 National Vaccine Plan Development: Recommendations From the National Vaccine Advisory Committee
Approved by the National Vaccine Advisory Committee on September 17, 2019
First Published February 14, 2020; pp. 181–188

The next big threat to global health? 2019 novel coronavirus (2019-nCoV): What advice can we give to travellers? – Interim recommendations January 2020, from the Latin-American society for Travel Medicine (SLAMVI)

Travel Medicine and Infectious Diseases
Volume 33 January–February 2020
https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/33/suppl/C

 

Editorial Full text access
The next big threat to global health? 2019 novel coronavirus (2019-nCoV): What advice can we give to travellers? – Interim recommendations January 2020, from the Latin-American society for Travel Medicine (SLAMVI)
Cristian Biscayart, Patricia Angeleri, Susana Lloveras, Tânia do Socorro Souza Chaves, … Alfonso J. Rodríguez-Morales
Article 101567

Environmental investigation of respiratory pathogens during the Hajj 2016 and 2018

Travel Medicine and Infectious Diseases
Volume 33 January–February 2020
https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/33/suppl/C

 

Research article Full text access
Environmental investigation of respiratory pathogens during the Hajj 2016 and 2018
Van-Thuan Hoang, Doudou Sow, Khadidja Belhouchat, Thi-Loi Dao, … Philippe Gautret
Article 101500

Measles-containing vaccines in Brazil: Coverage, homogeneity of coverage and associations with contextual factors at municipal level

Vaccine
Volume 38, Issue 8 Pages 1869-2114 (18 February 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/8

 

Short communication Abstract only
Measles-containing vaccines in Brazil: Coverage, homogeneity of coverage and associations with contextual factors at municipal level
Flávia C. Pacheco, Giovanny V.A. França, Guilherme A. Elidio, Mariana B. Leal, … Dirce B. Guilhem
Pages 1881-1887

Homeschooling parents in California: Attitudes, beliefs and behaviors associated with child’s vaccination status

Vaccine
Volume 38, Issue 8 Pages 1869-2114 (18 February 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/8

 

Research article Abstract only
Homeschooling parents in California: Attitudes, beliefs and behaviors associated with child’s vaccination status
Salini Mohanty, Caroline M. Joyce, Paul L. Delamater, Nicola P. Klein, … Alison M. Buttenheim
Pages 1899-1905

Identifying barriers and drivers to vaccination: A qualitative interview study with health workers in the Federation of Bosnia and Herzegovina

Vaccine
Volume 38, Issue 8 Pages 1869-2114 (18 February 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/8

 

Research article Open access
Identifying barriers and drivers to vaccination: A qualitative interview study with health workers in the Federation of Bosnia and Herzegovina
Sanjin Musa, Venesa Skrijelj, Aida Kulo, Katrine Bach Habersaat, … Cath Jackson
Pages 1906-1914

Influenza vaccine coverage and predictors of vaccination among aged care workers in Sydney Australia

Vaccine
Volume 38, Issue 8 Pages 1869-2114 (18 February 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/8

 

Research article Abstract only
Influenza vaccine coverage and predictors of vaccination among aged care workers in Sydney Australia
Elisa Lai, Hao Yi Tan, Mohana Kunasekaran, Abrar Ahmad Chughtai, … C. Raina MacIntyre
Pages 1968-1974

Safety of tetanus, diphtheria, and acellular pertussis vaccination among pregnant active duty U.S. military women

Vaccine
Volume 38, Issue 8 Pages 1869-2114 (18 February 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/8

 

Research articlennn Abstract only
Safety of tetanus, diphtheria, and acellular pertussis vaccination among pregnant active duty U.S. military women
Clinton Hall, Lisa M. Abramovitz, Anna T. Bukowinski, Ashley A. Ricker, … Ava Marie S. Conlin
Pages 1982-1988

Factors influencing Human papillomavirus (HPV) vaccination series completion in Mississippi Medicaid

Vaccine
Volume 38, Issue 8 Pages 1869-2114 (18 February 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/8

 

Research articlenn Abstract only
Factors influencing Human papillomavirus (HPV) vaccination series completion in Mississippi Medicaid
Sushmitha Inguva, Marie Barnard, Lori M. Ward, Yi Yang, … Sara L. Noble
Pages 2051-2057

An Exploratory Study of Influenza Vaccination Coverage in Healthcare Workers in a Western Chinese City, 2018–2019: Improving Target Population Coverage Based on Policy Interventions

Vaccines — Open Access Journal
http://www.mdpi.com/journal/vaccines
(Accessed 22 Feb 2020)

 

Open Access Article
Open Access Article
An Exploratory Study of Influenza Vaccination Coverage in Healthcare Workers in a Western Chinese City, 2018–2019: Improving Target Population Coverage Based on Policy Interventions
by Lili Xu , Jinhua Zhao , Zhibin Peng , Xiaojin Ding , Yonghong Li , Huayi Zhang , Huaxiang Feng , Jiandong Zheng , Hailan Cao , Binzhong Ma , Yan Shi , Yongcheng Ma and Luzhao Feng
Vaccines 2020, 8(1), 92; https://doi.org/10.3390/vaccines8010092 – 19 Feb 2020
Viewed by 114
Abstract
Objectives: To evaluate a policy-based intervention to increase seasonal-influenza-vaccination coverage in healthcare workers in Xining, a city in Western China.
Methods: From October 2018 to March 2019, we implemented a free vaccination policy in healthcare workers in Xining. A face-to-face interview with the head of the infection control department and an online survey for medical staff in four tertiary medical facilities was conducted to understand both the implementation of the free policy and influenza vaccination coverage. Possible factors for influenza vaccination among healthcare workers (physician, nurses working on the front-line, HCWs) were investigated by multivariate-logistic regression.
Results: Coverage in two hospitals that implemented the free vaccination policy was 30.5% and 25.9%, respectively, which was statistically different to hospitals that did not implement the free policy (7.2% and 8.7%, respectively) (χ2 = 332.56, p < 0.0001). Among vaccinated healthcare workers, 65.5% and 48.6% reported their main reasons for vaccination were a convenient vaccination service and awareness of the free vaccination policy. The reasons for not being vaccinated among the 3389 unvaccinated healthcare workers included: the inconvenient vaccination service (33.8%), believing vaccination was unnecessary (29.7%), concerns about adverse reactions to the vaccine (28.8%), and having to pay for the vaccine (25.6%).
Conclusions: Implementing the free vaccination policy, combined with improving the accessibility of the vaccination service, increased seasonal-influenza vaccination-coverage in healthcare workers in Xining